Maynadie M - Search Results

1

Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia.

Solary E, Caillot D, Chauffert B, Casasnovas RO, Dumas M, Maynadie M, Guy H. Solary E, et al. Among authors: maynadie m. J Clin Oncol. 1992 Nov;10(11):1730-6. doi: 10.1200/JCO.1992.10.11.1730. J Clin Oncol. 1992. PMID: 1357108

2

Multidrug resistance phenotype evaluation by immunofluorescence and functional tests: comparison of two monoclonal antibodies and three fluorescent dyes in three cells lines.

Maynadie M, Lizard G, Solary E, Roignot P, Carli PM. Maynadie M, et al. Anticancer Res. 1994 Nov-Dec;14(6B):2605-9. Anticancer Res. 1994. PMID: 7872688

3

[Value of rhodamine 123 in the detection of minor amounts of multidrug resistant cells].

Maynadié M, Lizard G, Solary E, Parmeland C, Carli PM. Maynadié M, et al. Bull Cancer. 1994 May;81(5):409-13. Bull Cancer. 1994. PMID: 7749218 French.

4

Prognostic relevance of surface markers in adult de novo acute myeloblastic leukemias: a prospective study of the Groupe d'Etude Immunologique des Leucémies (G.E.I.L.).

Casasnovas RO, Solary E, Campos L, Maynadie M, Favre M, Bremend JL, Garand R, Béné MC, Faure G. Casasnovas RO, et al. Among authors: maynadie m. Leuk Lymphoma. 1994;13 Suppl 1:7-10. doi: 10.3109/10428199409052665. Leuk Lymphoma. 1994. PMID: 8075584 No abstract available.

5

Systemic mast cell disease associated with hairy cell leukaemia.

Petrella T, Depret O, Arnould L, Maynadie M, Guy H, Dalac S, Caillot D, Casasnovas O, Lombard JN. Petrella T, et al. Among authors: maynadie m. Leuk Lymphoma. 1997 May;25(5-6):593-5. doi: 10.3109/10428199709039049. Leuk Lymphoma. 1997. PMID: 9250832

6

Immunological classification of acute myeloblastic leukemias: relevance to patient outcome.

Casasnovas RO, Slimane FK, Garand R, Faure GC, Campos L, Deneys V, Bernier M, Falkenrodt A, Lecalvez G, Maynadié M, Béné MC. Casasnovas RO, et al. Among authors: maynadie m. Leukemia. 2003 Mar;17(3):515-27. doi: 10.1038/sj.leu.2402821. Leukemia. 2003. PMID: 12646939

7

Der(16)t(1;16)(q10;p10) in multiple myeloma: a new non-random abnormality that is frequently associated with Burkitt's-type translocations.

Mugneret F, Sidaner I, Favre B, Manone L, Maynadié M, Caillot D, Solary E. Mugneret F, et al. Among authors: maynadie m. Leukemia. 1995 Feb;9(2):277-81. Leukemia. 1995. PMID: 7869764

8

Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes.

Audia S, Nicolas A, Cathelin D, Larmonier N, Ferrand C, Foucher P, Fanton A, Bergoin E, Maynadie M, Arnould L, Bateman A, Lorcerie B, Solary E, Chauffert B, Bonnotte B. Audia S, et al. Among authors: maynadie m. Clin Exp Immunol. 2007 Dec;150(3):523-30. doi: 10.1111/j.1365-2249.2007.03521.x. Epub 2007 Oct 22. Clin Exp Immunol. 2007. PMID: 17956583 Free PMC article. Clinical Trial.

9

Testing the proportional hazards assumption in medical survival studies--application to a population-based study of acute myeloid leukaemia.

Bourdais-Mannone C, Quantin C, Abrahamowicz M, Mannone L, Brunet-Lecomte P, Aho LS, Solary E, Maynadié M, Carli PM. Bourdais-Mannone C, et al. Among authors: maynadie m. J Epidemiol Biostat. 1999;4(2):83-92. J Epidemiol Biostat. 1999. PMID: 10619055

10

Immunophenotype in erythroleukemia secondary to myelodysplastic syndrome.

Maynadié M, Bailly F, Casasnovas RO, Coudert B, Carli PM. Maynadié M, et al. Blood. 1992 Aug 15;80(4):1097. Blood. 1992. PMID: 1463536 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

287 results

Search Page